A pragmatic 4.9-year follow-up of the SPRINT randomized trial compared fixed low- versus moderate-dose hydroxyurea for stroke prevention in sickle cell disease.
Recurrent stroke rates and all-cause mortality showed no significant differences between dosing groups over long-term observation.
Stroke and mortality events predominantly clustered within the first year of treatment initiation.
